Amerise Biosciences Ltd files Reg 29(2) disclosure on acquisition by Snehjeev Ventures & PACs

What Amerise Biosciences Ltd announced

Amerise Biosciences Ltd (formerly Amradeep Industries Ltd) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 with BSE on 16 July 2026. The filing informs the exchange that it has received a notice from Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) indicating an intention to acquire shares of Amerise.

The submission was made via email to the BSE’s Department of Corporate Services and is accompanied by a brief cover letter dated 16 July 2026. No further details—such as the number of shares sought, the percentage of holding, or the purchase price—are disclosed in the document.

Disclosure specifics

• Regulation invoked: 29(2) of SEBI (SAST) Regulations, 2011, which mandates that any party acquiring shares beyond a prescribed threshold must inform the stock exchange.
• Acquiring parties: Snehjeev Ventures Pvt Ltd and associated PACs.
• Filing date: 16 July 2026 (the filing was uploaded to BSE on 17 July 2026 at 05:11 UTC).
• Company details: Amerise Biosciences Ltd, CIN L29199GJ1984PLC007195, listed on BSE under scrip code 531681.
• Contact address: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad‑380014.

The filing does not contain any quantitative information about the proposed acquisition, nor does it indicate whether the acquirer has crossed the 5 % or 10 % shareholding thresholds that would trigger a mandatory open‑offer under SEBI rules.

Key facts at a glance

Why this matters for investors

Regulation 29(2) disclosures are a statutory requirement that alerts the market to potential changes in shareholding patterns. While the filing itself does not confirm that a transaction has been completed, it signals that an interested party has expressed intent to acquire shares. If the acquisition crosses SEBI‑prescribed thresholds (5 % for a single entity, 10 % for a group), the acquirer must make a public offer to all shareholders. Until such thresholds are met or a formal offer is announced, the impact on control, governance or share price remains uncertain.

Investors should monitor subsequent filings from Amerise Biosciences Ltd for any updates on the size of the stake being pursued, the consideration offered, and whether a mandatory open‑offer will be triggered.

Conclusion

Amerise Biosciences Ltd has complied with SEBI’s disclosure requirements by filing a Reg 29(2) notice on 16 July 2026 concerning a share acquisition proposal from Snehjeev Ventures Pvt Ltd and related PACs. The filing provides no quantitative details, and no offer has been announced. Stakeholders should await further disclosures that will clarify the scale of the intended acquisition and any consequent regulatory obligations.